Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients

Autor: R. ten Cate, T H C M Reinards, E W N Levarht, Marieke H Otten, René E. M. Toes, Jing Shi, Esther P A H Hoppenreijs, P. C. E. Hissink Muller, Sylvia Kamphuis, Leendert A. Trouw, J.M. van den Berg, J. Anink, C.M. Jol-van der Zijde, M. A. J. van Rossum, Koert M. Dolman, Marco W. Schilham, M.J.D. van Tol, Tom W J Huizinga, L.W.A. van Suijlekom-Smit, Cornelia F Allaart, D. M. C. Brinkman, Y. Koopman-Keemink
Přispěvatelé: Pediatrics, Immunology, Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology
Rok vydání: 2013
Předmět:
Zdroj: Annals of the Rheumatic Diseases, 72, 12, pp. 2053-5
Annals of the Rheumatic Diseases, 72(12), 2053-2055
Annals of the Rheumatic Diseases; Vol 72
Annals of the Rheumatic Diseases, 72(12), 2053-2055. BMJ Publishing Group
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 72(12), 2053-2055. BMJ Publishing Group
Annals of the Rheumatic Diseases, 72, 2053-5
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2013-203650
Popis: In juvenile idiopathic arthritis (JIA) patients there is a lack of markers that predict severe disease. Although anticitrullinated protein antibodies (ACPA) have contributed substantially to the understanding of rheumatoid arthritis (RA),1 their detection in JIA has not been equally useful as incidence rates in JIA patients are low2 and merely confined to the polyarticular immunoglobulin (Ig)M-rheumatoid factor (RF)-positive category resembling RA. Recently, anticarbamylated protein (anti-CarP) antibodies were detected in 45% of RA patients and importantly also in 16%–20% ACPA-negative patients.3–5 Within the ACPA-negative patients, anti-CarP antibodies were associated with more severe radiographic progression.3 Since most JIA patients are ACPA-negative we investigated whether anti-CarP antibodies are present in the sera of JIA patients and how they are related to ACPA and IgM-RF. JIA patients from three Dutch sources were included: the BeSt for Kids trial (NTR 1574, a treatment strategy study) (n=33), a previously described cohort6 (n=48) and the Arthritis and Biologicals in Children (ABC) register7 (n=153). Healthy controls (n=107) (mean age/range 11/(2–20)) are stem-cell graft …
Databáze: OpenAIRE